The incidence of melanoma is increasing worldwide, and the prognosis for patients with
high‐risk or advanced metastatic melanoma remains poor despite advances in the field …

Background Based on previous meta-analyses of randomized controlled trials (RCTs), the
use of interferon alpha (IFN-α) in the adjuvant setting improves disease-free survival (DFS) …

Most genetic susceptibility to cutaneous melanoma remains to be discovered. Meta-analysis
genome-wide association study (GWAS) of 36,760 cases of melanoma (67% newly …

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)
for Melanoma focuses on adjuvant therapy and treatment of in-transit disease, because …

Background Interferon alpha is the only agent approved for the postoperative adjuvant
treatment of high‐risk cutaneous melanoma. However, the survival advantage associated …

Purpose: Mucosal melanoma is rare and associated with extremely poor prognosis.
However, standard adjuvant therapy for mucosal melanoma has not been established. We …

Summation Cancer immunotherapy consists of approaches that modify the host immune
system, and/or the utilization of components of the immune system, as cancer treatment …

Background We assessed whether relapse-free survival (RFS; time until recurrence/death)
is a valid surrogate for overall survival (OS) among resected stage II–III melanoma patients …

Abstract Interferon (IFN) and PEG-IFN are the only drugs approved as adjuvant therapy in
patients with melanoma at high-risk of recurrence after surgical resection. Several clinical …

Cutaneous malignant melanoma (CMM) is the most life-threatening neoplasm of the skin
and is considered a major health problem as both incidence and mortality rates continue to …